We are live on ! Find out more

IQVIA

IQV

Market cap $43.7B

265.67 USD

+3.90

1.49%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

265.67

0.00

0%

1 day

1.49%

5 days

0.63%

1 month

12.26%

3 months

48.93%

6 months

61.12%

Year to date

17.88%

1 year

42.86%

5 years

3.15%

10 years

241.04%

About: Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Employees: 94,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.5%

Neutral 37.2%

Negative 9.3%

Zacks Investment Research

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term

IQVIA Announces Pricing of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and e.

IQVIA Announces Pricing of Senior Notes

IQVIA Announces Offering of Senior Notes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses relate.

IQVIA Announces Offering of Senior Notes

IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical.

IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial executio.

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare

Zacks Investment Research

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?

Zacks Investment Research

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing proble.

IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology cover.

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group

Zacks Investment Research

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

See News Rankings

Price charts implemented using Lightweight Charts™